Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 3
Submit an article Journal homepage
2,287
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma

Faye A. SharpleyDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; View further author information
,
Faouzi DjebbariDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; ORCID Iconhttp://orcid.org/0000-0001-9578-7632View further author information
ORCID Icon,
Samih FouraliDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; View further author information
,
Jaimal KothariDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; ;NIHR Oxford Biomedical Research Centre Blood Theme, Oxford, UK; View further author information
,
John A. LynesCelgene Ltd, Uxbridge, UK; View further author information
,
Susan McLain-SmithpH Associates Ltd, Marlow, UKView further author information
&
Karthik RamasamyDepartment of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; ;NIHR Oxford Biomedical Research Centre Blood Theme, Oxford, UK; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-3385-3707View further author information
ORCID Icon show all
Pages 732-736 | Received 22 Jul 2019, Accepted 14 Oct 2019, Published online: 27 Nov 2019

References

  • National Institute for Health and Care Excellence. 2011. Bortezomib and thalidomide for the first-line treatment of multiple myeloma (TA228). [cited 2019 Apr 12]. Available from: https://www.nice.org.uk/guidance/ta228.
  • National Institute for Health and Care Excellence, 2018. Myeloma: diagnosis and management (NG35). [cited 2019 Apr 12]. Available from: https://www.nice.org.uk/guidance/ng35.
  • Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906–917.
  • Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131(3):301–310.
  • Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–1473.
  • Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
  • Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759–1769.
  • Palumbo A, Bringhen S, Larocca A, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. JCO. 2014;32(7):634–640.
  • Manier S, Robinson S, Owen M, et al. Efficacy of lenalidomide and low-dose dexamethasone in newly diagnosed patients with multiple myeloma: results from a meta-analysis of randomized controlled trial evidence. HemaSphere. 2019;3:272.
  • Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175(2):252–264.
  • Mühlbacher AC, Lincke HJ, Nübling M. Evaluating patients’ preferences for multiple myeloma therapy, a discrete-choice-experiment. Psychosoc Med. 2008;5:Doc10.
  • Acaster S, Gaugris S, Velikova G, et al. Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey. Support Care Cancer. 2013;21(2):599–607.
  • Despiégel N, Touboul C, Flinois A, et al. Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France. Clin Lymphoma Myeloma Leuk. 2019;19(1):e13–e28.
  • Zou Y, Sheng Z, Niu S, et al. Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma. Leuk Lymphoma. 2013;54(10):2219–2225.
  • Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011;118(5):1231–1238.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.